Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 5/20 | 0.53 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.53 |
| ▸ | CMA1 | P23946 | 2/20 | 0.47 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | TDP2 | O95551 | 3/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | CASP9 | P55211 | 1/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.37 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.37 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.36 |
| ▸ | PGR | P06401 | 2/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.36 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL443143 | 0.84 | AHR (0.53) | AHRPDK2CMA1EIF2AK2PDE3B | |
| SCHEMBL910409 | 0.82 | NPC1 (0.55) | PDE3BPDE3ACRBNNPC1MAPK13 | |
| SCHEMBL1450276 | 0.79 | MAPT (0.58) | AHRPDK2CRBNNPC1MAPK13 | |
| SCHEMBL27459742 | 0.77 | TDP2 (0.56) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL3352684 | 0.73 | PDE3B (0.42) | PDE3BPDE3ACRBNCYP11B1CYP11B2 | |
| Oxindole SCHEMBL8866524 | 0.72 | AHR (0.95) | AHRPDK2CMA1EIF2AK2PDE3B | |
| Oxindole SCHEMBL15636313 | 0.72 | AHR (0.95) | AHRPDK2CMA1EIF2AK2PDE3B | |
| SCHEMBL16907887 | 0.72 | AHR (0.48) | AHRPDK2CMA1EIF2AK2PDE3B | |
| SCHEMBL3353117 | 0.72 | CYP11B1 (0.38) | PDE3BPDE3ACYP11B1CYP11B2 | |
| SCHEMBL986343 | 0.71 | NPC1 (0.55) | AHRPDK2PDE3BPDE3ACRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 555 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2023-05-11 | — | — | US | claimed |
| CN-107072205-B | SMYD inhibitors | EPIZYME股份有限公司 | 2022-07-15 | — | — | CN | claimed |
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | claimed |
| EP-3639823-A1 | SUBSTITUTED 2-(4-HETEROCYCLYLBENZYL)ISOINDOLIN-1-ONE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | Vanderbilt University Center for Technology Transfer and Commercialization (US) | 2020-04-22 | — | — | EP | claimed |
| US-20200048195-A1 | SUBSTITUTED PYRROLIDINE CARBOXAMIDE COMPOUNDS | Epizyme, Inc. | 2020-02-13 | — | — | US | claimed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | claimed |
| EP-2373318-B1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2019-06-05 | — | — | EP | claimed |
| US-10092583-B2 | Imidazopyridines Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2018-10-09 | — | — | US | claimed |
| EP-2912037-B1 | 2-AMINOPYRIDINE COMPOUNDS | MERCK PATENT GMBH (DE) | 2018-08-22 | — | — | EP | claimed |
| EP-2970258-B1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE DEUTSCHLAND (DE) | 2018-04-18 | — | — | EP | claimed |
| WO-2004089903-A9 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | WARNER LAMBERT CO (US) | 2005-10-27 | — | — | WO | claimed |
| EP-1537084-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | Amgen Inc. (US) | 2005-06-08 | — | — | EP | claimed |
| US-20050070534-A1 | Non-peptidic NPY Y2 receptor inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-31 | — | — | US | claimed |
| US-20040214832-A1 | Piperazine derivative renin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-28 | — | — | US | claimed |
| WO-2004089903-A1 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | claimed |
| WO-2004089915-A1 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | claimed |
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-14 | — | — | US | claimed |
| WO-2004007458-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC. (US) | 2004-01-22 | — | — | WO | claimed |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-12-04 | — | — | US | claimed |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-09-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10092583-B2 | Imidazopyridines Syk inhibitors | SYK, BTK, ZAP70 | AHR 2731/4885PDK2 2087/4885CMA1 431/4885 |
| US-20230148214-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, GDI2 | AHR 1804/4885PDK2 463/4885CMA1 3848/4885 |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | AHR 69/4885PDK2 2434/4885CMA1 466/4885 |
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | REN, ACE, HPN | AHR 4200/4885PDK2 989/4885CMA1 636/4885 |
| US-20040214832-A1 | Piperazine derivative renin inhibitors | REN, ACE, AGTR2 | AHR 3067/4885PDK2 463/4885CMA1 275/4885 |
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | AHR 2472/4885PDK2 1991/4885CMA1 2659/4885 |
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | AHR 1942/4885PDK2 2163/4885CMA1 2308/4885 |
| US-20200048195-A1 | SUBSTITUTED PYRROLIDINE CARBOXAMIDE COMPOUNDS | SMYD3, SMYD2, SMURF2 | AHR 3247/4885PDK2 826/4885CMA1 3389/4885 |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | COL1A1, MKI67, INSR | AHR 410/4885PDK2 2732/4885CMA1 856/4885 |
| US-20050070534-A1 | Non-peptidic NPY Y2 receptor inhibitors | NPY2R, NPY1R, NPY5R | AHR 3065/4885PDK2 2001/4885CMA1 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.